PE20231312A1 - Derivados triciclicos de carboxamida como inhibidores de la prmt5 - Google Patents
Derivados triciclicos de carboxamida como inhibidores de la prmt5Info
- Publication number
- PE20231312A1 PE20231312A1 PE2023001721A PE2023001721A PE20231312A1 PE 20231312 A1 PE20231312 A1 PE 20231312A1 PE 2023001721 A PE2023001721 A PE 2023001721A PE 2023001721 A PE2023001721 A PE 2023001721A PE 20231312 A1 PE20231312 A1 PE 20231312A1
- Authority
- PE
- Peru
- Prior art keywords
- optionally substituted
- independently selected
- case
- alkyl
- compounds
- Prior art date
Links
- 102100034607 Protein arginine N-methyltransferase 5 Human genes 0.000 title abstract 2
- 101710084427 Protein arginine N-methyltransferase 5 Proteins 0.000 title abstract 2
- 229940053202 antiepileptics carboxamide derivative Drugs 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 2
- 229910052799 carbon Inorganic materials 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 abstract 1
- 150000007578 6-membered cyclic compounds Chemical group 0.000 abstract 1
- 208000019838 Blood disease Diseases 0.000 abstract 1
- WBWDKPRFVWYYCO-UHFFFAOYSA-N NC1=NC(C=CC(C(N(CC2CC2)CC2=NC=C(C(F)(F)F)C=C2)=O)=C2)=C2C2=C1COC2 Chemical compound NC1=NC(C=CC(C(N(CC2CC2)CC2=NC=C(C(F)(F)F)C=C2)=O)=C2)=C2C2=C1COC2 WBWDKPRFVWYYCO-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 125000001475 halogen functional group Chemical group 0.000 abstract 1
- 208000014951 hematologic disease Diseases 0.000 abstract 1
- 208000018706 hematopoietic system disease Diseases 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- -1 hydroxy, amino Chemical group 0.000 abstract 1
- 239000013067 intermediate product Substances 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 230000002503 metabolic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002062 proliferating effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000003107 substituted aryl group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Referido a un compuesto de Formula I, un tautomero del mismo, un esteroisomero del mismo o una sal farmaceuticamente aceptable de cualquiera de los anteriores, en donde: R es un triciclo independientemente seleccionado de las formulas IA y IB, en donde la linea punteada es un enlace sencillo o doble; X1, X2, X6 y X7 son en cada caso N o C, en donde tanto X1 como X2 no pueden ser N al mismo tiempo, y en donde si X1 es C, puede estar opcionalmente sustituido con halo; X3, X4 y X5 se seleccionan en cada caso independientemente de un C, O, N y S opcionalmente sustituidos; R3 en cada caso se selecciona independientemente de H o alquilo C1-3; Ar1 es un arilo o heteroarilo opcionalmente sustituido de seis miembros; R1 en cada caso se selecciona independientemente de H, halo, alquilo C1-3 opcionalmente sustituido; entre otros; R2 en cada caso se selecciona independientemente de un alquilo C1-8 opcionalmente sustituido, ciclo o heterociclo de 5 o 6 miembros opcionalmente sustituido con hidroxi, amino, entre otros. Un compuesto seleccionado es 4-amino-N-(ciclopropilmetil)-N-((5-(trifluorometil)-2-piridinil)metil)-1,3-dihidrofuro[3,4-c]quinolin-8-carboxamida. Estos compuestos son derivados triciclicos de carboxamida, y son inhibidores de la PRMT5. Tambien se refiere a metodos de sintesis de dichos compuestos, productos intermedios, composiciones farmaceuticas que comprenden dichos compuestos, y su uso en el tratamiento de trastornos proliferativos, tales como cancer, trastornos metabolicos y sanguineos.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063117937P | 2020-11-24 | 2020-11-24 | |
| PCT/US2021/060332 WO2022115377A1 (en) | 2020-11-24 | 2021-11-22 | Tricyclic carboxamide derivatives as prmt5 inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20231312A1 true PE20231312A1 (es) | 2023-08-24 |
Family
ID=78957958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2023001721A PE20231312A1 (es) | 2020-11-24 | 2021-11-22 | Derivados triciclicos de carboxamida como inhibidores de la prmt5 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240101570A1 (es) |
| EP (1) | EP4251624A1 (es) |
| JP (1) | JP2023550466A (es) |
| KR (1) | KR20230113339A (es) |
| CN (1) | CN116783191A (es) |
| AU (1) | AU2021386149A1 (es) |
| CA (1) | CA3202141A1 (es) |
| CL (1) | CL2023001461A1 (es) |
| CO (1) | CO2023007504A2 (es) |
| CR (1) | CR20230286A (es) |
| IL (1) | IL302820A (es) |
| MX (1) | MX2023006145A (es) |
| PE (1) | PE20231312A1 (es) |
| WO (1) | WO2022115377A1 (es) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11077101B1 (en) | 2018-07-18 | 2021-08-03 | Tango Therapeutics, Inc. | Compounds and methods of use |
| AU2021319201A1 (en) | 2020-07-31 | 2023-02-16 | Tango Therapeutics, Inc. | Piperidin-1-yl-n-pyridin-3-yl-2-oxoacetamide derivatives useful for the treatment of mtap-deficient and/or mta-accumulating cancers |
| CN116462677A (zh) * | 2022-01-20 | 2023-07-21 | 上海和誉生物医药科技有限公司 | 一种多稠环prmt5抑制剂及其制备方法和应用 |
| WO2023246873A1 (zh) * | 2022-06-23 | 2023-12-28 | 南京明德新药研发有限公司 | 氨基取代的杂芳基衍生物及其应用 |
| WO2024002376A1 (zh) * | 2022-07-01 | 2024-01-04 | 上海赛岚生物科技有限公司 | 一类prmt5抑制剂及其用途 |
| WO2024008113A1 (zh) * | 2022-07-07 | 2024-01-11 | 深圳微芯生物科技股份有限公司 | 一种甲酰胺取代的杂三环类衍生物、其制备方法及其应用 |
| WO2024027370A1 (zh) * | 2022-08-03 | 2024-02-08 | 上海和誉生物医药科技有限公司 | 一种含氮三稠环prmt5抑制剂，其制备方法和药学上的用途 |
| WO2024038004A1 (en) | 2022-08-15 | 2024-02-22 | Astrazeneca Ab | Mta-cooperative prmt5 inhibitors for use in the treatment of cancer |
| WO2024137852A1 (en) * | 2022-12-22 | 2024-06-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| WO2024131901A1 (zh) * | 2022-12-23 | 2024-06-27 | 深圳微芯生物科技股份有限公司 | 一类含炔基取代的杂环酰胺衍生物、其制备方法及其应用 |
| US11858935B1 (en) | 2023-09-06 | 2024-01-02 | King Faisal University | Pyrrolo[2,3-c][1,7]naphthyridine-2-carboxylic acid compounds as CK2 inhibitors |
| US11891394B1 (en) | 2023-09-06 | 2024-02-06 | King Faisal University | Pyrrolo[2,3-c][1,6]naphthyridine-8-carboxylic acid compounds as CK2 inhibitors |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201604022D0 (en) * | 2016-03-09 | 2016-04-20 | Ctxt Pty Ltd | Compounds |
-
2021
- 2021-11-22 CR CR20230286A patent/CR20230286A/es unknown
- 2021-11-22 AU AU2021386149A patent/AU2021386149A1/en active Pending
- 2021-11-22 JP JP2023530598A patent/JP2023550466A/ja active Pending
- 2021-11-22 CN CN202180091440.0A patent/CN116783191A/zh active Pending
- 2021-11-22 PE PE2023001721A patent/PE20231312A1/es unknown
- 2021-11-22 WO PCT/US2021/060332 patent/WO2022115377A1/en active Application Filing
- 2021-11-22 IL IL302820A patent/IL302820A/en unknown
- 2021-11-22 KR KR1020237021023A patent/KR20230113339A/ko unknown
- 2021-11-22 US US18/255,575 patent/US20240101570A1/en active Pending
- 2021-11-22 EP EP21827727.5A patent/EP4251624A1/en active Pending
- 2021-11-22 MX MX2023006145A patent/MX2023006145A/es unknown
- 2021-11-22 CA CA3202141A patent/CA3202141A1/en active Pending
-
2023
- 2023-05-22 CL CL2023001461A patent/CL2023001461A1/es unknown
- 2023-06-06 CO CONC2023/0007504A patent/CO2023007504A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CO2023007504A2 (es) | 2023-09-08 |
| IL302820A (en) | 2023-07-01 |
| US20240101570A1 (en) | 2024-03-28 |
| EP4251624A1 (en) | 2023-10-04 |
| CA3202141A1 (en) | 2022-06-02 |
| WO2022115377A1 (en) | 2022-06-02 |
| KR20230113339A (ko) | 2023-07-28 |
| CL2023001461A1 (es) | 2023-12-01 |
| CN116783191A (zh) | 2023-09-19 |
| CR20230286A (es) | 2023-08-24 |
| MX2023006145A (es) | 2023-06-06 |
| AU2021386149A1 (en) | 2023-06-22 |
| JP2023550466A (ja) | 2023-12-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20231312A1 (es) | Derivados triciclicos de carboxamida como inhibidores de la prmt5 | |
| AR127309A2 (es) | Derivados de piridazinona | |
| PE20220931A1 (es) | Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina | |
| AR107714A1 (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| ES2594409T3 (es) | Derivados de heteroarilo como moduladores del nAChR á7 | |
| AR070636A1 (es) | Derivados de piridina, composicion farmaceutica y uso terapeutico | |
| AR034203A1 (es) | Derivados de 1-aril- o 1-alquilsulfonilbenzazol como ligandos de 5-hidroxitriptamina-6, un metodo para su preparacion, composicion farmaceutica y el uso de los mismos para la fabricacion de un medicamento | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| AR102722A2 (es) | Un derivado de pirazolo-quinazolina, su uso, un procedimiento para prepararlos, composiciones farmacéuticas que los comprenden, compuestos utilizables en su preparación, una biblioteca de dos o más compuestos, y un producto o kit | |
| AR055303A1 (es) | Derivados de triazol sustituidos como antagonistas de oxitocina, composicion farmaceutica y uso del compuesto para preparar un medicamento | |
| PE20142216A1 (es) | Inhibidores de indazol de la ruta de senalizacion de wnt y usos terapeuticos de los mismos | |
| AR033306A1 (es) | Compuestos | |
| AR111314A1 (es) | Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue | |
| AR038476A1 (es) | Derivados de quinazolina | |
| PE20210414A1 (es) | Compuestos inhibidores de rip1 y metodos para preparar y usar los mismos | |
| AR030553A1 (es) | Uso de derivados de tiazolilo 2,4-disustituidos para la fabricacion de un medicamento para la prevencion o el tratamiento de enfermedades mediadas a traves de citoquinas, derivados de tiazolilo 2,4-disustituidos, composiciones farmaceuticas que los comprenden, procesos para preparar dichos derivados | |
| AR045595A1 (es) | Composiciones utiles como inhibidores de proteinas quinasas | |
| EA200400615A1 (ru) | Производные амидов в качестве ингибиторов гликогенсинтаза-киназы 3-бета | |
| AR047076A1 (es) | Compuestos de pirrolotriazina como inhibidores de tirosina quinasas, composiciones farmaceuticas | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR081058A1 (es) | Derivados de arilmetoxi isoindolina, composiciones que los comprenden y su uso en el tratamiento del cancer. | |
| AR063602A1 (es) | Derivados de espiroindolinona, formulaciones farmaceuticas que los contienen y su uso en la obtencion de un medicamento para el tratamiento de trastornos oncologicos. | |
| AR087052A1 (es) | Derivados de amina ciclica como antagonistas del receptor ep4 | |
| AR057855A1 (es) | Derivados de pirazina y composicion farmaceutica | |
| AR114679A1 (es) | Compuestos heterocíclicos fungicidas |